DSE : RENATA

Renata PLC

Pharmaceutical Preparations · Bangladesh

Last price 425.9 BDT (At close: Oct 29, 2026) · Market cap 48.85B

Latest research: Renata valuation report: fair value BDT 146–350 (Oct 2026) · Renata's FY2026 recovery is real, but a 10% return on equity supports BDT 146–350 a share (base 234)

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh and Portugal. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxi...

Technical report: trend, RSI, support and resistance, charts

Reports